Figure 1.
Typical TEM images of optimized formulation 1 (a) and optimized formulation 2 (b) showing the structure of the nanoparticles.
Figure 1.
Typical TEM images of optimized formulation 1 (a) and optimized formulation 2 (b) showing the structure of the nanoparticles.
Figure 2.
(a) Typical particle size and size distribution of nanoparticles, (b) Zeta potential of nanoparticles.
Figure 2.
(a) Typical particle size and size distribution of nanoparticles, (b) Zeta potential of nanoparticles.
Figure 3.
Overlay of FT-IR spectra of blank nanoparticles (black), brusatol- and docetaxel-loaded nanoparticles (red), pure brusatol (dark blue), pure docetaxel (green), PLGA-PEG polymer (purple), physical admixture (blue).
Figure 3.
Overlay of FT-IR spectra of blank nanoparticles (black), brusatol- and docetaxel-loaded nanoparticles (red), pure brusatol (dark blue), pure docetaxel (green), PLGA-PEG polymer (purple), physical admixture (blue).
Figure 4.
In vitro drug release profile of brusatol- and docetaxel-loaded nanoparticles in PBS at 37 ± 1 °C (n = 3; data represent mean ± SD).
Figure 4.
In vitro drug release profile of brusatol- and docetaxel-loaded nanoparticles in PBS at 37 ± 1 °C (n = 3; data represent mean ± SD).
Figure 5.
Percent cell viability of (a) LNCaP cells; (b) PC-3 cells treated with brusatol and docetaxel in vitro at 72 h (mean ± SD; n = 4). Control represents media only and DMSO represents 0.01% DMSO in media. Statistical analysis by two-way ANOVA and Paired t-test * p < 0.05.
Figure 5.
Percent cell viability of (a) LNCaP cells; (b) PC-3 cells treated with brusatol and docetaxel in vitro at 72 h (mean ± SD; n = 4). Control represents media only and DMSO represents 0.01% DMSO in media. Statistical analysis by two-way ANOVA and Paired t-test * p < 0.05.
Figure 6.
Evaluation of cytotoxicity of docetaxel- and brusatol-loaded nanoparticles and controls at different concentrations by automated viable cell count. (a) LNCaP cells (24 h), (b) PC-3 cells (24 h), (c) LNCaP cells (72 h), (d) PC-3 cells (72 h). Data are mean ± SD (n = 3).
Figure 6.
Evaluation of cytotoxicity of docetaxel- and brusatol-loaded nanoparticles and controls at different concentrations by automated viable cell count. (a) LNCaP cells (24 h), (b) PC-3 cells (24 h), (c) LNCaP cells (72 h), (d) PC-3 cells (72 h). Data are mean ± SD (n = 3).
Figure 7.
In vitro evaluation of cytotoxicity of combination drug solution, and combination drug-loaded nanoparticles containing the same concentration of drugs as the solution, and other controls at different concentrations of drugs using the MTS assay. (a) LNCaP cells (24 h), (b) PC-3 cells (24 h), (c) LNCaP cells (72 h), (d) PC-3 cells (72 h). Data are mean ± SD (n = 3). Statistical analysis by 2-way ANOVA and Paired t-test * p < 0.05.
Figure 7.
In vitro evaluation of cytotoxicity of combination drug solution, and combination drug-loaded nanoparticles containing the same concentration of drugs as the solution, and other controls at different concentrations of drugs using the MTS assay. (a) LNCaP cells (24 h), (b) PC-3 cells (24 h), (c) LNCaP cells (72 h), (d) PC-3 cells (72 h). Data are mean ± SD (n = 3). Statistical analysis by 2-way ANOVA and Paired t-test * p < 0.05.
Figure 8.
Effect of DMSO solution, blank-NPs, brusatol-40 nM, docetacel-60 nM, docetacel-60 nM + brusatol-40 nM solution, and docetacel-60 nM + brusatol-40 nM nanoparticles on cell cycle distribution of LNCaP cells post treatment (a) 24 h, (b) 72 h, (c) 120 h, (d) showing the population of cells in subG1-phase at 120 h post-treatment (n = 3). Statistical analysis by Brown-Forsythe ANOVA with Welch’s ANOVA test * p ≤ 0.05, *** p ≤ 0.001, **** p ≤ 0.0001. ns means “not significant”.
Figure 8.
Effect of DMSO solution, blank-NPs, brusatol-40 nM, docetacel-60 nM, docetacel-60 nM + brusatol-40 nM solution, and docetacel-60 nM + brusatol-40 nM nanoparticles on cell cycle distribution of LNCaP cells post treatment (a) 24 h, (b) 72 h, (c) 120 h, (d) showing the population of cells in subG1-phase at 120 h post-treatment (n = 3). Statistical analysis by Brown-Forsythe ANOVA with Welch’s ANOVA test * p ≤ 0.05, *** p ≤ 0.001, **** p ≤ 0.0001. ns means “not significant”.
Figure 9.
Representative flow cytometry histograms of cell cycle analysis of LNCaP cells treated with (
a) Control (
b) DMSO, (
c) blank-NPs, (
d) brusatol-40 nM, (
e) docetaxel-60 nM, (
f) docetaxel-60 nM + brusatol-40 nM solution, (
g) docetaxel-60 nM + brusatol-40 nM nanoparticles and incubated for 24 h. Table of average values is presented in the
supporting information (Table S1).
Figure 9.
Representative flow cytometry histograms of cell cycle analysis of LNCaP cells treated with (
a) Control (
b) DMSO, (
c) blank-NPs, (
d) brusatol-40 nM, (
e) docetaxel-60 nM, (
f) docetaxel-60 nM + brusatol-40 nM solution, (
g) docetaxel-60 nM + brusatol-40 nM nanoparticles and incubated for 24 h. Table of average values is presented in the
supporting information (Table S1).
Figure 10.
Effect of DMSO solution, blank-NPs-60 nM, brusatol-40 nM, docetaxel-60 nM, docetaxel-60 nM + brusatol-40 nM solution, and docetaxel-60 nM + brusatol-40 nM nanoparticles on cell cycle distribution of PC-3 cells post treatment (a) 24 h, (b) 72 h, (c) 120 h, (d) the population of cells in subG1-phase at 120 h post-treatment (n = 3). Statistical analysis by Brown-Forsythe ANOVA with Welch’s ANOVA test ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. ns means “not significant”.
Figure 10.
Effect of DMSO solution, blank-NPs-60 nM, brusatol-40 nM, docetaxel-60 nM, docetaxel-60 nM + brusatol-40 nM solution, and docetaxel-60 nM + brusatol-40 nM nanoparticles on cell cycle distribution of PC-3 cells post treatment (a) 24 h, (b) 72 h, (c) 120 h, (d) the population of cells in subG1-phase at 120 h post-treatment (n = 3). Statistical analysis by Brown-Forsythe ANOVA with Welch’s ANOVA test ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. ns means “not significant”.
Figure 11.
Representative flow cytometry histograms of cell cycle analysis of PC-3 cells treated with (
a) control, (
b) DMSO solution, (
c) blank-NPs, (
d) brusatol-40 nM, (
e) docetacel-60 nM, (
f) docetacel-60 nM + brusatol-40 nM solution, (
g) docetacel-60 nM + brusatol-40 nM nanoparticles and incubated for 24 h. Table of average values is presented in the
supporting information (Table S1).
Figure 11.
Representative flow cytometry histograms of cell cycle analysis of PC-3 cells treated with (
a) control, (
b) DMSO solution, (
c) blank-NPs, (
d) brusatol-40 nM, (
e) docetacel-60 nM, (
f) docetacel-60 nM + brusatol-40 nM solution, (
g) docetacel-60 nM + brusatol-40 nM nanoparticles and incubated for 24 h. Table of average values is presented in the
supporting information (Table S1).
Figure 12.
Caspase 3/7 activity in LNCaP cells treated with blank-NPs, brusatol-40 nM, docetaxel-60 nM, docetaxel-60 nM + brusatol-40 nM solution, and docetaxel-60 nM + brusatol-40 nM nanoparticles and incubated for 72 h. (a) Dot plot of caspase 3/7 activity, (b) Percentage of caspase 3/7 activity, (c) Percentage of total cell death, (d) Phase contrast images of treated cells; (×40 Magnification). Statistical analysis by Brown-Forsythe ANOVA with Welch’s ANOVA test * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. ns means “not significant”.
Figure 12.
Caspase 3/7 activity in LNCaP cells treated with blank-NPs, brusatol-40 nM, docetaxel-60 nM, docetaxel-60 nM + brusatol-40 nM solution, and docetaxel-60 nM + brusatol-40 nM nanoparticles and incubated for 72 h. (a) Dot plot of caspase 3/7 activity, (b) Percentage of caspase 3/7 activity, (c) Percentage of total cell death, (d) Phase contrast images of treated cells; (×40 Magnification). Statistical analysis by Brown-Forsythe ANOVA with Welch’s ANOVA test * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. ns means “not significant”.
Figure 13.
Caspase 3/7 activity in PC-3 cells treated with blank-NPs, brusatol-40 nM, docetaxel-60 nM, docetaxel-60 nM + brusatol-40 nM solution, and docetaxel-60 nM + brusatol-40 nM nanoparticles and incubated for 72 h. (a) Dot plot of caspase 3/7 activity, (b) Percentage of caspase 3/7 activity, (c) Percentage of total death, (d) Phase contrast images of treated cells; (×40 Magnification). Statistical analysis by Brown-Forsythe ANOVA with Welch’s ANOVA test * p ≤ 0.05, ** p ≤ 0.01. ns means “not significant”.
Figure 13.
Caspase 3/7 activity in PC-3 cells treated with blank-NPs, brusatol-40 nM, docetaxel-60 nM, docetaxel-60 nM + brusatol-40 nM solution, and docetaxel-60 nM + brusatol-40 nM nanoparticles and incubated for 72 h. (a) Dot plot of caspase 3/7 activity, (b) Percentage of caspase 3/7 activity, (c) Percentage of total death, (d) Phase contrast images of treated cells; (×40 Magnification). Statistical analysis by Brown-Forsythe ANOVA with Welch’s ANOVA test * p ≤ 0.05, ** p ≤ 0.01. ns means “not significant”.
Figure 14.
Immunoblotting assay: Western blot analysis for survivin to evaluate the effect of the different drug treatments on survivin expression using tubulin as control. (a) LNCaP cells at 24 h, (b) LNCaP cells at 72 h, after treatment with brusatol (40 nM), docetaxel (60 nM), combination drug solution (40 nM brusatol + 60 nM docetaxel), and nanoparticle formulations containing the same concentration of drugs as in the combination drug solution.
Figure 14.
Immunoblotting assay: Western blot analysis for survivin to evaluate the effect of the different drug treatments on survivin expression using tubulin as control. (a) LNCaP cells at 24 h, (b) LNCaP cells at 72 h, after treatment with brusatol (40 nM), docetaxel (60 nM), combination drug solution (40 nM brusatol + 60 nM docetaxel), and nanoparticle formulations containing the same concentration of drugs as in the combination drug solution.
Table 2.
Feed composition of drug-loaded nanoparticles (n = 3).
Table 2.
Feed composition of drug-loaded nanoparticles (n = 3).
Formulation | Docetaxel (mg) | Brusatol (mg) | Drug:Polymer (%) |
---|
1 | 7 | 3 | 20% |
2 | 6 | 4 | 20% |
3 | 5 | 5 | 20% |
4 | 4 | 6 | 20% |
5 | 2.5 | 7.5 | 20% |
6 | 3 | 7 | 20% |
7 | 2 | 8 | 20% |
8 | 1 | 9 | 20% |
9 | 4.5 | 10.5 | 30% |
10 | 3 | 12 | 30% |
Table 3.
Particle size data from initial screening experiments using the one-factor-at-a time method.
Table 3.
Particle size data from initial screening experiments using the one-factor-at-a time method.
Formulation Factor | Variation | Size (nm) | Process Factor | Variation | Size (nm) |
---|
Solvent composition | Ethyl acetate:DMF | 202.8 | Pulse (on/off, sec) | No pulse | 188.7 |
| Ethyl acetate:acetone | 206.9 | | 7:3 | 230.8 |
| Ethyl acetate:DMSO | 212.8 | | 8:2 | 178.1 |
| Ethyl acetate:ACN | 207.6 | | 9:1 | 175.9 |
Solvent ratio | 1.2:0.8 | 371.6 | Amplitude (%) | 25 | 176.9 |
| 1.4:0.6 | 391 | | 30 | 196.1 |
| 1.6:0.4 | 179.2 | | 35 | 193.3 |
| 1.8:0.2 | 200.4 | | 40 | 203.8 |
Polymer conc. | 20 mg/2 mL | 207.1 | Sonic. time (min) | 2.5 | 199.3 |
| 50 mg/2 mL | 189.6 | | 5 | 188.8 |
| 75 mg/2 mL | 185.7 | | 7.5 | 186.8 |
| 100 mg/2 mL | 194.5 | | 10 | 186.1 |
| 150 mg/2 mL | 355.1 | | | |
Organic:Aqueous | 2:8 | 203 | | | |
| 2:10 | 193.4 | | | |
| 2:12 | 192.1 | | | |
| 2:14 | 318.5 | | | |
| 2:16 | 399.4 | | | |
PVA conc. (%) | 0.25 | 186.9 | | | |
| 0.5 | 182.1 | | | |
| 1 | 184.5 | | | |
| 2 | 195 | | | |
| 3 | 195 | | | |
Table 4.
Full factorial statistical experimental design for the preparation of nanoparticles generated by Minitab® with mean particle size and PDI of nanoparticle formulations.
Table 4.
Full factorial statistical experimental design for the preparation of nanoparticles generated by Minitab® with mean particle size and PDI of nanoparticle formulations.
Formulation | Polymer Conc. (mg/2 mL) | Organic:Aqu | PVA Conc. (%) | Amplitude (%) | Size (nm) | Polydispersity |
---|
1 | 25 | 2|8 | 1.5 | 30 | 225.2 | 0.149 |
2 | 50 | 2|8 | 0.5 | 30 | 212.5 | 0.048 |
3 | 25 | 2|8 | 1.5 | 26 | 230.4 | 0.134 |
4 | 50 | 2|8 | 1.5 | 26 | 201.7 | 0.104 |
5 | 50 | 2|8 | 1.5 | 30 | 206.7 | 0.049 |
6 | 37.5 | 2|10 | 1 | 28 | 195 | 0.081 |
7 | 25 | 2|8 | 0.5 | 30 | 220.5 | 0.064 |
8 | 50 | 2|8 | 1.5 | 30 | 212.9 | 0.058 |
9 | 50 | 2|12 | 0.5 | 30 | 203.3 | 0.067 |
10 | 25 | 2|12 | 1.5 | 26 | 186.7 | 0.128 |
11 | 25 | 2|8 | 1.5 | 26 | 223.8 | 0.105 |
12 | 37.5 | 2|10 | 1 | 28 | 201.8 | 0.088 |
13 | 50 | 2|12 | 1.5 | 26 | 185.6 | 0.032 |
14 | 37.5 | 2|10 | 1 | 28 | 190.6 | 0.116 |
15 | 50 | 2|8 | 0.5 | 26 | 197.8 | 0.089 |
16 | 25 | 2|12 | 1.5 | 30 | 177.3 | 0.102 |
17 | 50 | 2|12 | 0.5 | 30 | 181.6 | 0.059 |
18 | 25 | 2|8 | 1.5 | 30 | 210.5 | 0.098 |
19 | 25 | 2|12 | 1.5 | 26 | 158.4 | 0.08 |
20 | 25 | 2|12 | 0.5 | 30 | 173.3 | 0.114 |
21 | 37.5 | 2|10 | 1 | 28 | 184.9 | 0.046 |
22 | 50 | 2|12 | 1.5 | 30 | 181 | 0.085 |
23 | 25 | 2|12 | 0.5 | 26 | 173.7 | 0.042 |
24 | 25 | 2|8 | 0.5 | 26 | 203.3 | 0.079 |
25 | 50 | 2|8 | 0.5 | 30 | 192.3 | 0.089 |
26 | 25 | 2|12 | 1.5 | 30 | 170.4 | 0.093 |
27 | 37.5 | 2|10 | 1 | 28 | 175.1 | 0.147 |
28 | 25 | 2|8 | 0.5 | 30 | 186 | 0.075 |
29 | 25 | 2|12 | 0.5 | 30 | 167.7 | 0.119 |
30 | 25 | 2|8 | 0.5 | 26 | 181.9 | 0.079 |
31 | 50 | 2|12 | 0.5 | 26 | 173.1 | 0.069 |
32 | 50 | 2|12 | 1.5 | 26 | 172.7 | 0.077 |
33 | 50 | 2|8 | 1.5 | 26 | 184.1 | 0.106 |
34 | 50 | 2|12 | 1.5 | 30 | 176 | 0.061 |
35 | 25 | 2|12 | 0.5 | 26 | 171.7 | 0.105 |
36 | 50 | 2|8 | 0.5 | 26 | 183.8 | 0.138 |
37 | 50 | 2|12 | 0.5 | 26 | 159.6 | 0.071 |
Table 5.
Analysis of variance table.
Table 5.
Analysis of variance table.
Analysis of Variance |
---|
Source | DF | Adj SS | Adj MS | F-Value | p-Value |
---|
Model | 6 | 9113.7 | 1518.94 | 10.91 | 0.000 |
Linear | 4 | 7926.1 | 1981.54 | 14.23 | 0.000 |
Pol. Conc. (mg/2 mL) | 1 | 62.7 | 62.72 | 0.45 | 0.507 |
Org:Aqueous | 1 | 6903.1 | 6903.12 | 49.59 | 0.000 |
PVA Conc. (%) | 1 | 528.1 | 528.12 | 3.79 | 0.061 |
Amp (%) | 1 | 432.2 | 432.18 | 3.10 | 0.088 |
2-Way Interactions | 2 | 1187.5 | 593.75 | 4.27 | 0.023 |
Pol. Conc. (mg/2 mL) * Org:Aqueous | 1 | 723.9 | 723.90 | 5.20 | 0.030 |
Org:Aqueous * PVA Conc. (%) | 1 | 463.6 | 463.60 | 3.33 | 0.078 |
Error | 30 | 4176.4 | 139.21 | | |
Curvature | 1 | 4.4 | 4.36 | 0.03 | 0.863 |
Lack-of-Fit | 9 | 1301.2 | 144.58 | 1.01 | 0.466 |
Pure Error | 20 | 2870.8 | 143.54 | | |
Total | 36 | 13,290.1 | | | |
Table 6.
Response optimization showing predicted and experimental mean particle size data (n = 3).
Table 6.
Response optimization showing predicted and experimental mean particle size data (n = 3).
Solution | Pol. Conc. (mg/2 mL) | Org:Aqu | PVA Conc. (%) | Amp (%) | Predicted Particle Size (nm) | Composite Desirability | Experimental Mean Particle Size (nm) |
---|
1 | 25 | 0.167 | 0.5 | 26 | 168.333 | 0.868436 | 169.09 |
2 | 50 | 0.1670 | 0.5 | 26 | 175.046 | 0.77953 | 175.15 |
Table 7.
Feed amount of brusatol and docetaxel and mean particle size and percent loading of each drug using the optimized nanoparticle formulation (n = 3).
Table 7.
Feed amount of brusatol and docetaxel and mean particle size and percent loading of each drug using the optimized nanoparticle formulation (n = 3).
Formulation | Doc (mg) | Bru (mg) | Size (nm) | Doc Loading (%) | Bru Loading (%) | Drug:Polymer (%) |
---|
1 | 7 | 3 | 201.87 ± 1.40 | 7.84 ± 0.17 | 0.87 ± 0.17 | 20% |
2 | 6 | 4 | 195.70 ± 1.15 | 6.37 ± 0.11 | 0.79 ± 0.07 | 20% |
3 | 5 | 5 | 198.27 ± 2.78 | 6.32 ± 0.11 | 1.14 ± 0.03 | 20% |
4 | 4 | 6 | 182.57 ± 1.90 | 3.73 ± 0.25 | 0.82 ± 0.09 | 20% |
5 | 3 | 7 | 194.97 ± 0.75 | 2.49 ± 0.13 | 0.79 ± 0.08 | 20% |
6 | 2.5 | 7.5 | 184.80 ± 1.30 | 2.04 ± 0.04 | 0.89 ± 0.02 | 20% |
7 | 2 | 8 | 188.80 ± 0.80 | 1.41 ± 0.17 | 0.99 ± 0.15 | 20% |
8 | 1 | 9 | 193.83 ± 1.59 | 0.70 ± 0.06 | 1.48 ± 0.28 | 20% |
9 | 4.5 | 10.5 | 185.07 ± 3.55 | 3.33 ± 0.96 | 0.89 ± 0.19 | 30% |
10 | 3 | 12 | 183.03 ± 5.66 | 1.88 ± 0.57 | 0.92 ± 0.30 | 30% |
Table 8.
CI data of combination brusatol and docetaxel solution (50:50) in LNCaP and PC-3 cell lines.
Table 8.
CI data of combination brusatol and docetaxel solution (50:50) in LNCaP and PC-3 cell lines.
Total Dose (nM) | CI in LNCaP Cells | CI in PC-3 Cells |
---|
5.0 | 0.33061 | 0.10535 |
10.0 | 0.59098 | 0.18948 |
20.0 | 0.64905 | 0.33766 |
40.0 | 0.76064 | 0.29589 |
80.0 | 0.79381 | 0.55168 |
160.0 | 0.95830 | 0.99662 |